WiMi Studies Quantum Hybrid Neural Network Model to Empower Intelligent Image Classification BEIJING, Jan. 15, 2026––WiMi Hologram Cloud Inc. (NASDAQ: WiMi) ("WiMi" or the "Company"), a leading global ...

About the LUCE-1 Trial LUCE-1 is a Phase 1/2 multicenter, open-label, dose escalation study investigating safety, tolerability and preliminary efficacy of 3 dose levels of dual AAV8.MYO7A (AAVB-081) ...

DVRE cuts MaxSAT encoding size offline and clauses online, delivering the fastest complete MBD on ISCAS-85 for both single- ...

The firm at the JP Morgan Healthcare Conference additionally expects a regulatory decision on its gene therapy RGX-121 for Hunter syndrome next month.

The FDA granted fast track status to VectorY’s VTx-002, an antibody gene therapy targeting TDP-43 protein aggregates in ALS.

A new clinical study published in the International Journal of Gynecological Cancer reports encouraging results for women ...

Despite having plenty of information and knowledge, I struggled to put everything together, so I turned to AI to help create ...

TG4050 elicits strong polyepitopic, polyclonal, durable cytotoxic and effector neoantigen-specific CD8 T cell responses Results reinforce TG4050 potential as an individualized cancer immunotherapy ...

The human brain is often compared to a computer, but the latest wave of research shows it is closer to a self-building city, ...

As retail AI spreads beyond pilots, leaders are learning that better forecasts are not enough. Trust and judgment define what ...

AP31969 is a novel, first-in-class, oral SK ion channel inhibitor intended for rhythm control of atrial fibrillation and has recently completed Phase 1 in ...

MicroCloud Hologram Inc. (NASDAQ: HOLO), ("HOLO" or the "Company"), a technology service provider, released learnable quantum spectral filter technology for hybrid graph neural networks. This ...